)
10X Genomics (TXG) investor relations material
10X Genomics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue was $150.7M, up 1% YoY; consumables and services growth offset lower instrument and license revenue, while gross margin rose to 75% and net loss narrowed to $19.4M.
Atera commercial shipments began in September; strong demand supported raised FY26 guidance, but production, installation and training capacity are expected to constrain the ramp.
Financial highlights
Q3 revenue was $150.7M versus $149.0M; products and services revenue rose 1% to $150.2M, while license and royalty revenue fell 54% to $0.5M.
Operating loss improved to $16.1M from $32.2M, and net loss narrowed to $19.4M from $27.5M.
Operating expenses fell 3% to $129.0M from $132.5M; lower personnel and lab equipment costs were partly offset by higher litigation expenses.
9M revenue declined 5% to $452.5M from $476.8M, while net loss widened to $50.8M from $27.3M.
Outlook and guidance
FY26 revenue guidance rose to $625M–$635M from $610M–$630M; excluding non-recurring patent-settlement revenue in FY26 and FY25, expected growth is 4%–6%.
Year-end Atera shipment outlook rose to ~50 instruments from ~40; capacity constraints make ~50 per quarter a reasonable 2027 ramp expectation.
Q4 gross margin is expected in the low-to-mid 60% range, pressured by product mix and Atera shipments; 2027 margins are expected below current levels as placements precede consumables growth.
Q4 spatial consumables are expected to grow at a double-digit rate, including a full quarter of Atera consumables shipments.
Planned capital expenditures are $10M–$15M over the next 12 months, mainly for manufacturing and R&D equipment; existing cash and cash generation are expected to cover needs for at least 12 months.
- Q2 2026 revenue up 3% YoY (excl. settlements), gross margin 74%, guidance raised to $610–$630M.TXG
Q2 2026 - Q1 2026 revenue up 9% adjusted, gross margin at 70%, and Atera launch drives strong demand.TXG
Q1 2026 - Q4 revenue beat guidance as consumables surged, but instrument sales lagged amid CapEx headwinds.TXG
Q4 2025 - Q3 2025 revenue hit $149M, with strong spatial growth and improved margins amid macro headwinds.TXG
Q3 2025 - Q2 revenue up 13% with $68M settlement; Scale Biosciences acquisition and funding headwinds noted.TXG
Q2 2025 - Q3 revenue fell 1% as spatial consumables soared and instruments lagged amid restructuring.TXG
Q3 2024 - Q2 revenue up 4% to $153.1M; guidance lowered amid macro headwinds and restructuring.TXG
Q2 2024 - Q1 2025 revenue $154.9M–$155M, core down 2%, guidance withdrawn amid funding uncertainty.TXG
Q1 2025 - 2024 revenue dipped 1% as new products launched; 2025 outlook is flat with NIH risks.TXG
Q4 2024
Next 10X Genomics earnings date
Next 10X Genomics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)